Fierce Pharma
J&J's Caplyta supersizes its reach with FDA nod as add-on treatment for major depressive disorder
Caplyta, the crown jewel of Johnson & Johnson's $14.6 billion buyout of Intra-Cellular Therapies, won the FDA’s blessing to ...
Stocktwits on MSN
Johnson & Johnson’s Newly Acquired Antipsychotic Drug Approved By FDA For Major Depressive Disorder
The new approval is the first for the drug under JNJ leadership. ・The drug is also approved for the treatment of bipolar I ...
Pharmaceutical Technology on MSN
J&J’s Caplyta wins MDD approval to extend revenue horizon
The US Food and Drug Administration (FDA) has approved Caplyta as an adjunctive therapy with antidepressants for the ...
pharmaphorum
J&J adds first new indication for Caplyta since takeover
The US regulator has cleared Caplyta (lumateperone) as an adjunctive therapy with antidepressants for the treatment of major ...
J&J brain drug acquired in $14.6B buyout cleared for broader use
Caplyta, which J&J got in its acquisition of Intra-Cellular Therapies, netted a clearance in major depressive disorder that’s key to achieving the $5 billion in annualized sales the company expects.